<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michelle Lai, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjiv Chopra, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lin H Chen, MD, FACP, FASTMH, FISTM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 01, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis A infection is caused by the hepatitis A virus (HAV) Humans are the only known reservoir. HAV infection is usually a self-limited illness that does not become chronic. Fulminant hepatic failure occurs in less than 1 percent of cases. Infection confers lifelong immunity and is preventable via vaccination.
        </p>
        <p>
         HAV is a member of the genus
         <em>
          Hepatovirus
         </em>
         in the family
         <em>
          Picornaviridae
         </em>
         . Two clinical forms of hepatitis were recognized in 1947 and designated hepatitis A and hepatitis B [
         <a href="#rid1">
          1
         </a>
         ]; subsequently, the virus that causes hepatitis A was identified in 1973 [
         <a href="#rid2">
          2
         </a>
         ]. Other terms previously used for HAV infection include epidemic jaundice, acute catarrhal jaundice, and campaign jaundice.
        </p>
        <p>
         The epidemiology, clinical manifestations, diagnosis, and treatment of HAV infection in adults are reviewed here. Issues related to HAV vaccination are presented separately, as are issues related to HAV in children and pregnant women. (See
         <a class="medical medical_review" href="/z/d/html/3900.html" rel="external">
          "Hepatitis A virus infection: Treatment and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5942.html" rel="external">
          "Overview of hepatitis A virus infection in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3564.html" rel="external">
          "Overview of coincident acute hepatobiliary disease in pregnant women", section on 'Hepatitis A virus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H1288931367">
         <span class="h2">
          Transmission and risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         HAV is usually transmitted by the fecal-oral route (either via person-to-person contact or consumption of contaminated food or water). HAV can remain infectious on hands for several hours, on foods for several days, and on frozen foods, surfaces, and in feces for several months [
         <a href="#rid3">
          3-8
         </a>
         ]. Risk factors for HAV transmission are summarized in the table  (
         <a class="graphic graphic_table graphicRef80824" href="/z/d/graphic/80824.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid9">
          9-13
         </a>
         ]. Maternal-fetal transmission has not been described.
        </p>
        <p>
         Fulminant hepatic failure develops in fewer than 1 percent of patients with hepatitis A [
         <a href="#rid14">
          14
         </a>
         ]; important risk factors include age &gt;50 years and underlying liver disease (particularly chronic hepatitis C virus infection) [
         <a href="#rid15">
          15-17
         </a>
         ]. In one study including 163 patients with chronic hepatitis B and 432 patients with chronic hepatitis C, hepatitis A superinfection occurred in 27 patients [
         <a href="#rid17">
          17
         </a>
         ]. Among 17 patients with hepatitis C who acquired hepatitis A, fulminant hepatic failure developed in seven cases, of whom six died. Among 10 patients with hepatitis B who acquired hepatitis A, nine had uncomplicated infection; one patient developed marked cholestasis in the setting of pre-existing cirrhosis.
        </p>
        <p class="headingAnchor" id="H922608184">
         <span class="h2">
          Distribution and outbreaks
         </span>
         <span class="headingEndMark">
          —
         </span>
         HAV infection occurs worldwide. Globally, an estimated 159 million new HAV infections leading to 39,000 fatalities occur each year [
         <a href="#rid18">
          18,19
         </a>
         ]. Hepatitis A can occur sporadically or in an epidemic form [
         <a href="#rid20">
          20
         </a>
         ]. Updated information on outbreaks may be found on websites maintained by the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Ffoodnet%2Freports%2Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLP%2F2QvaEIA4SKO0gOEuf1VgY0YkeS8eQxq4ypPiI8NSzyeT%2FmnPtuFxMsoc8brVKag%3D%3D&amp;TOPIC_ID=2692" target="_blank">
          United States Centers for Disease Control and Prevention
         </a>
         and the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Ffood%2Frecalls-outbreaks-emergencies%2Foutbreaks-foodborne-illness&amp;token=RnGqCfYGTGgdz5387EFWwvy4g0FBsVH2%2F8GNTYjMB5LrJLowNdHBE3AHH5VQdHvjZEGstInrU%2FzZFkdijUOFBBVMo%2FciHvaLQZ9RU37rpBQ%3D&amp;TOPIC_ID=2692" target="_blank">
          US Food and Drug Administration
         </a>
         .
        </p>
        <p>
         Hepatitis outbreaks have occurred in a variety of settings, including community outbreaks due to contaminated water or food (cooked foods can transmit HAV if the cooking temperature is inadequate to kill the virus or if food is contaminated after cooking) [
         <a href="#rid21">
          21-27
         </a>
         ], outbreaks in health care settings, and outbreaks among homeless individuals [
         <a href="#rid28">
          28-31
         </a>
         ].
        </p>
        <p>
         After the implementation of vaccination in certain segments of the population in the United States, there was a steady decline in the incidence of HAV until 2014, after which the number of estimated new infections has increased. In 2019, the estimated number of infections had increased to 15 times that of 2014. This increase is due to outbreaks among individuals who report drug use or homelessness, among men who have sex with men, and outbreaks associated with contaminated food [
         <a href="#rid32">
          32,33
         </a>
         ]. In 2017, more than 650 individuals in California were infected with hepatitis A (including 417 hospitalizations and 21 deaths), making this the largest outbreak in the United States in two decades [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         International outbreaks have occurred via importation of contaminated food from areas where HAV is endemic [
         <a href="#rid23">
          23-25,27,35
         </a>
         ]. In some circumstances, seemingly sporadic occurrences may reflect cases from geographically distant outbreaks. In one report, for example, 213 cases of hepatitis A were detected from 23 schools in Michigan and 29 cases from 13 schools in Maine; all were related to contaminated frozen strawberries from a common source [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1355076005">
         <span class="h2">
          Impact of vaccination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of HAV has declined substantially since implementation of vaccination:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the United States, since vaccination was recommended for individuals at increased risk for infection (in 1996), for children living in states with the highest incidence of HAV (in 1999), and for all infants (in 2006), the incidence of acute hepatitis A declined between 1999 and 2014, from 6 to 0.4 cases per 100,000 [
         <a href="#rid9">
          9,15,37-42
         </a>
         ]. However, between 2014 and 2017, incidence increased to 1 per 100,000 persons [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In China, the incidence among individuals age ≤19 years in one province declined to a historically low rate in 2014, while the highest incidence rate was observed in those aged ≥20 years [
         <a href="#rid43">
          43
         </a>
         ]. In addition, improvement of living conditions in resource-limited settings has been associated with fewer child infections, leading to a larger population of adults who lack protective antibodies and are at risk for outbreaks  (
         <a class="graphic graphic_figure graphicRef69392" href="/z/d/graphic/69392.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatic injury occurs as a result of the host immune response to HAV. Viral replication occurs in the hepatocyte cytoplasm; hepatocellular damage and destruction of infected hepatocytes is mediated by human leukocyte antigen-restricted, HAV-specific CD8+ T lymphocytes and natural killer cells [
         <a href="#rid44">
          44-46
         </a>
         ]. Interferon-gamma appears to have a central role in promoting clearance of infected hepatocytes [
         <a href="#rid44">
          44
         </a>
         ]. An excessive host response (denoted by a marked reduction of circulation HAV ribonucleic acid (RNA) during acute infection) is associated with severe hepatitis [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3024115574">
         <span class="h2">
          Typical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute HAV infection in adults is usually a self-limited illness; fulminant hepatic failure occurs in fewer than 1 percent of cases. The incubation period of hepatitis A infection averages 28 days (range 15 to 50 days) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         Symptomatic illness due to HAV occurs in more than 70 percent of adults. Symptoms are uncommon in children &lt;6 years of age.
        </p>
        <p>
         Symptoms and signs begin with abrupt onset of nausea, vomiting, anorexia, fever, malaise, and abdominal pain  (
         <a class="graphic graphic_figure graphicRef57931" href="/z/d/graphic/57931.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid49">
          49
         </a>
         ]. Within a few days to a week, dark urine (bilirubinuria) appears; pale stools (lacking bilirubin pigment) may also be observed. These are followed by jaundice and pruritus (40 to 70 percent of cases). The early signs and symptoms usually diminish when jaundice appears, and jaundice typically peaks within two weeks.
        </p>
        <p>
         Physical findings include jaundice, scleral icterus, hepatomegaly (80 percent of cases), and right upper quadrant tenderness to palpation [
         <a href="#rid20">
          20,50
         </a>
         ]. Less common findings include splenomegaly and extrahepatic manifestations such as skin rash and arthralgias. (See
         <a class="local">
          'Extrahepatic manifestations'
         </a>
         below.)
        </p>
        <p>
         In pregnant women, acute hepatitis A infection has been associated with increased risk of preterm labor and gestational complications [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         No specific disease manifestations in immunocompromised hosts have been described.
        </p>
        <p>
         Laboratory abnormalities include elevations of serum aminotransferases (often &gt;1000 international units/dL), serum bilirubin (typically ≤10 mg/dL), and alkaline phosphatase (up to 400 U/L) [
         <a href="#rid50">
          50
         </a>
         ]. The serum aminotransferase elevations precede the bilirubin elevation. Serum alanine aminotransferase is commonly higher than the serum aspartate aminotransferase. Serum aminotransferases peak approximately one month after exposure to the virus and then decline by approximately 75 percent per week [
         <a href="#rid52">
          52
         </a>
         ]. The serum bilirubin concentration usually declines within two weeks of peak levels [
         <a href="#rid20">
          20
         </a>
         ]. Other laboratory abnormalities include elevations of acute-phase reactants and inflammatory markers.
        </p>
        <p>
         Infected individuals are contagious during the incubation period and remain so for about a week after jaundice appears [
         <a href="#rid53">
          53
         </a>
         ]. HAV replicates in the liver and is shed in the stool in high concentrations from two to three weeks before to one week after onset of clinical illness  (
         <a class="graphic graphic_figure graphicRef57931" href="/z/d/graphic/57931.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         Full clinical and biochemical recovery is observed within two to three months in 85 percent of patients, and complete recovery is observed by six months in nearly all patients [
         <a href="#rid52">
          52
         </a>
         ]. HAV infection does not become chronic, and individuals cannot become reinfected after recovering from infection. However, relapse can occur. (See
         <a class="local">
          'Relapsing hepatitis'
         </a>
         below.)
        </p>
        <p>
         Fulminant hepatic failure refers to the development of severe acute liver injury with encephalopathy and impaired synthetic function (international normalized ratio ≥1.5). It occurs most commonly in individuals &gt;50 years of age and individuals with other liver diseases such as hepatitis B or C [
         <a href="#rid14">
          14
         </a>
         ]. Such patients may require liver transplant. (See
         <a class="medical medical_review" href="/z/d/html/3574.html" rel="external">
          "Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H42342034">
         <span class="h2">
          Extrahepatic manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several extrahepatic manifestations associated with HAV infection have been described. Extrahepatic manifestations occur most commonly in patients who have protracted illness such as relapsing or cholestatic hepatitis [
         <a href="#rid54">
          54,55
         </a>
         ]. (See
         <a class="local">
          'Cholestatic hepatitis'
         </a>
         below and
         <a class="local">
          'Relapsing hepatitis'
         </a>
         below.)
        </p>
        <p>
         The most common extrahepatic manifestations include evanescent rash and arthralgias (occurring in 10 to 15 percent of patients).
        </p>
        <p>
         Other conditions related to immune complex disease and vasculitis occur rarely, including [
         <a href="#rid54">
          54-59
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leukocytoclastic vasculitis (most often apparent on the legs and buttocks; biopsy demonstrates anti-HAV immunoglobulin (Ig)M and complement in the blood vessel walls)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arthritis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glomerulonephritis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cryoglobulinemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optic neuritis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transverse myelitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Toxic epidermal necrolysis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myocarditis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aplastic anemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Red cell aplasia
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2658326809">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications of acute hepatitis A infection include cholestatic hepatitis, relapsing hepatitis, and autoimmune hepatitis [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2677603502">
         <span class="h3">
          Cholestatic hepatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prolonged cholestasis is characterized by a protracted period of jaundice (lasting &gt;3 months); it occurs among fewer than 5 percent of patients with acute hepatitis A infection [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
         The course of cholestatic hepatitis is usually characterized by marked jaundice, pruritus, fever, weight loss, diarrhea, and malaise [
         <a href="#rid50">
          50,56,60,62
         </a>
         ]. Laboratory findings include markedly elevated serum bilirubin (often &gt;10 mg/dL) and alkaline phosphatase, modest elevation of serum aminotransferases (5 to 15 times the upper limit of normal), and elevated serum cholesterol. Peak bilirubin levels may be reached in the eighth week or later.
        </p>
        <p>
         In general, cholestatic hepatitis resolves spontaneously with no sequelae; recognition is important to avoid unnecessary testing. Ultrasonography is appropriate to exclude biliary obstruction; cholangiography or liver biopsy are usually not necessary [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Treatment is usually supportive; there is no role for corticosteroids [
         <a href="#rid56">
          56,60
         </a>
         ].
         <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">
          Cholestyramine
         </a>
         may be administered if pruritus is bothersome. (See
         <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">
          "Pruritus associated with cholestasis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1914349308">
         <span class="h3">
          Relapsing hepatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Up to 10 percent of patients experience a relapse of symptoms during the six months after acute illness [
         <a href="#rid56">
          56,63-67
         </a>
         ]. The duration of clinical relapse is generally less than three weeks, although biochemical relapse may last as long as 12 months [
         <a href="#rid67">
          67
         </a>
         ]. The cause of relapsing hepatitis is unknown, and no predisposing factors for relapse have been identified [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         The clinical course usually consists of apparent clinical recovery after acute infection with near normalization of the serum aminotransferases, followed by biochemical (and, in some cases, clinical) relapse; clinical manifestations of relapse are often milder than the initial episode [
         <a href="#rid63">
          63
         </a>
         ]. Serum aminotransferases may exceed 1000 international units/dL, and serum anti-HAV IgM antibodies typically persist throughout the course of the disease [
         <a href="#rid63">
          63,68
         </a>
         ]. HAV can be recovered from stool during relapse episodes, so such patients should be considered infectious [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         Multiple relapses can occur. In one series including 297 adults with acute hepatitis A infection, relapse was observed in 13 percent of patients (of whom 22 percent had more than one relapse); approximately half of patients were asymptomatic during the relapses [
         <a href="#rid64">
          64
         </a>
         ]. Development of extrahepatic manifestations (such as arthritis, vasculitis, nephritis, and cryoglobulinemia) during relapse has been described [
         <a href="#rid54">
          54,57
         </a>
         ]. (See
         <a class="local">
          'Extrahepatic manifestations'
         </a>
         above.)
        </p>
        <p>
         In general, patients with relapsing hepatitis have complete recovery; recognition is important to avoid unnecessary testing. Ultrasonography is appropriate to exclude biliary obstruction in patients with significant jaundice; cholangiography or liver biopsy are usually not necessary.
        </p>
        <p class="headingAnchor" id="H3399532467">
         <span class="h3">
          Autoimmune hepatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, HAV infection may serve as a trigger for development of autoimmune hepatitis in susceptible individuals [
         <a href="#rid69">
          69,70
         </a>
         ]. Autoimmune hepatitis is a chronic hepatitis characterized by hyperglobulinemia, the presence of circulating autoantibodies (such as anti-nuclear, anti-smooth muscle, and/or anti-actin antibodies), and inflammatory changes on liver histology.
        </p>
        <p>
         Issues related to autoimmune hepatitis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3665.html" rel="external">
          "Overview of autoimmune hepatitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of acute HAV infection should be suspected in patients with abrupt onset of prodromal symptoms (nausea, anorexia, fever, malaise, or abdominal pain) and jaundice or elevated serum aminotransferase levels, particularly in the setting of known risk factors for hepatitis A transmission  (
         <a class="graphic graphic_table graphicRef80824" href="/z/d/graphic/80824.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         The diagnosis is established by detection of serum IgM anti-HAV antibodies. Serum IgM antibodies are detectable at the time of symptom onset, peak during the acute or early convalescent phase of the disease, and remain detectable for approximately three to six months  (
         <a class="graphic graphic_figure graphicRef57931" href="/z/d/graphic/57931.html" rel="external">
          figure 2
         </a>
         ). Among patients with relapsing hepatitis, serum IgM antibodies persist for the duration of this disease. (See
         <a class="local">
          'Relapsing hepatitis'
         </a>
         above.)
        </p>
        <p>
         Detection of serum IgM antibodies in the absence of clinical symptoms may reflect prior HAV infection with prolonged persistence of IgM, a false-positive result, or asymptomatic infection (which is more common in children &lt;6 years of age than in older children or adults) [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Serum IgG antibodies appear early in the convalescent phase of the disease, remain detectable for decades, and are associated with lifelong protective immunity  (
         <a class="graphic graphic_figure graphicRef57931" href="/z/d/graphic/57931.html" rel="external">
          figure 2
         </a>
         ). Detection of anti-HAV IgG in the absence of anti-HAV IgM reflects past infection or vaccination rather than acute infection.
        </p>
        <p>
         Imaging studies are generally not indicated for diagnosis of HAV infection. Ultrasonography may sometimes be appropriate to rule out alternative diagnoses (such as biliary obstruction); cholangiography or liver biopsy are usually not indicated.
        </p>
        <p class="headingAnchor" id="H5389616">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of HAV infection includes other viruses that can cause hepatitis, all of which may be distinguished by serology:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatitis B, C, D, and E – Hepatitis A and E are acute infections transmitted by the fecal-oral route, whereas hepatitis B and C can present acutely or chronically and are transmitted by body fluids. Infection with hepatitis D virus can lead to acute hepatitis in patients with hepatitis B virus infection. (See related topics.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epstein-Barr virus and cytomegalovirus – Both Epstein-Barr virus and cytomegalovirus may present with liver function abnormalities as well as fever, fatigue, and lymphadenopathy. (See
         <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">
          "Infectious mononucleosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Yellow fever virus – Yellow fever virus is transmitted by mosquitoes in endemic regions; initial manifestations consist of malaise and other nonspecific symptoms, followed by acute illness with fever, jaundice, and gastrointestinal manifestations. (See
         <a class="medical medical_review" href="/z/d/html/3032.html" rel="external">
          "Yellow fever: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Herpes simplex virus – Hepatitis is a rare complication of herpes simplex virus infection. It may present fulminantly, most commonly in immunocompromised hosts. Occasionally hepatic involvement may develop in the absence of coincident rash. (See
         <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Hepatitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adenovirus – Adenovirus infection typically involves the respiratory and gastrointestinal tracts; hepatitis may be a complication of adenovirus infection in immunocompromised hosts. (See
         <a class="medical medical_review" href="/z/d/html/8339.html" rel="external">
          "Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Gastrointestinal system'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human immunodeficiency virus (HIV) infection – Patients with acute HIV infection may have nausea, diarrhea, and anorexia. More serious gastrointestinal manifestations such as hepatitis can occur though rarely. (See
         <a class="medical medical_review" href="/z/d/html/86984.html" rel="external">
          "Acute and early HIV infection: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other infectious causes of fever and jaundice include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malaria – Malaria is a mosquito-borne parasitic infection characterized by fever, anemia, and parasitemia; clinical manifestations include jaundice due to hemolysis. The diagnosis may be established by examination of the peripheral blood smear. (See
         <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">
          "Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leptospirosis – Leptospirosis is a bacterial infection characterized by fever, myalgia, headache, and conjunctival suffusion. Modest elevation of hepatic transaminases may be observed. The diagnosis is established by serology. (See
         <a class="medical medical_review" href="/z/d/html/5527.html" rel="external">
          "Leptospirosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Syphilis – Syphilis is a sexually transmitted infection; secondary syphilis consists of several clinical manifestations including elevated serum alkaline phosphatase, often with normal or only slightly abnormal transaminases. The diagnosis is established by serology. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Q fever – Q fever results from infection with
         <em>
          Coxiella burnetii
         </em>
         ; hepatic involvement includes transaminitis, hepatomegaly without jaundice, and granulomas on liver biopsy. The diagnosis is established by serology.
        </p>
        <p>
        </p>
        <p>
         Noninfectious entities with presentations similar to hepatitis A infection include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcoholic hepatitis – Clinical features of alcoholic hepatitis include jaundice, anorexia, fever, and tender hepatomegaly. Laboratory testing demonstrates moderately elevated transaminases (typically less than 300 international units/mL), with an aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio of two or greater. Patients may also present with right upper quadrant/epigastric pain, hepatic encephalopathy, and signs of malnutrition. (See
         <a class="medical medical_review" href="/z/d/html/86934.html" rel="external">
          "Alcoholic hepatitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug-induced liver injury (DILI) – Liver injury can be associated with many drugs. Patients with DILI may be asymptomatic with abnormal liver function tests or have malaise, anorexia, nausea, vomiting, right upper quadrant pain, dark urine, acholic stools, jaundice, and pruritus. The diagnosis may be established via liver biopsy. (See
         <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">
          "Drug-induced liver injury"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Budd-Chiari syndrome – Budd-Chiari syndrome is defined as hepatic venous outflow tract obstruction. Patients with Budd-Chiari syndrome may present with acute or subacute liver disease or acute liver failure. The diagnosis is established via ultrasonography. (See
         <a class="medical medical_review" href="/z/d/html/3562.html" rel="external">
          "Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune hepatitis – Autoimmune hepatitis may be asymptomatic or present with nonspecific symptoms, such as malaise, anorexia, nausea, abdominal pain, itching, and arthralgia. The diagnosis is established via serologic testing and histology. (See
         <a class="medical medical_review" href="/z/d/html/3665.html" rel="external">
          "Overview of autoimmune hepatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wilson disease – Wilson disease is a genetic disorder characterized by excess copper; it can present as acute hepatitis, jaundice, abdominal pain, and elevated transaminase levels (typically &lt;2000 international units/dL with an AST/ALT ratio &gt;2). The diagnosis is based on serum ceruloplasmin and copper levels and ocular slit-lamp examination for Kayser-Fleisher rings. (See
         <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">
          "Wilson disease: Clinical manifestations, diagnosis, and natural history"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H607549528">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115404.html" rel="external">
          "Society guideline links: Travel medicine"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16201.html" rel="external">
          "Patient education: Hepatitis A (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4572.html" rel="external">
          "Patient education: Hepatitis A (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7717987">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         − Hepatitis A is caused by the hepatitis A virus (HAV) and has a worldwide distribution. HAV is typically transmitted by the fecal-oral route (either via person-to-person contact or consumption of contaminated food or water). Risk factors for HAV transmission include residence in or travel to areas with poor sanitation, household or sexual contact with another person with hepatitis A, exposure to daycare centers, exposure to residential institutions, and intravenous drug use  (
         <a class="graphic graphic_table graphicRef80824" href="/z/d/graphic/80824.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Typical manifestations
         </strong>
         − The incubation period of HAV averages 28 days (range 15 to 50 days). Most adults with HAV infection have symptomatic illness which begins with abrupt onset of nausea, anorexia, fever, malaise, and abdominal pain. Within a few days to a week, dark urine and acholic stools appear, followed by jaundice and pruritus. The early clinical manifestations usually diminish when jaundice appears, and jaundice typically peaks within two weeks. Hepatitis A is usually a self-limited illness that does not become chronic (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complications and extrahepatic manifestations
         </strong>
         − Complications of acute hepatitis A infection include cholestatic hepatitis, relapsing hepatitis, and autoimmune hepatitis. Extrahepatic manifestations include evanescent rash, arthralgias, and other conditions related to immune complex disease and vasculitis. (See
         <a class="local">
          'Extrahepatic manifestations'
         </a>
         above and
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fulminant hepatic failure
         </strong>
         − Fulminant hepatic failure occurs in fewer than 1 percent of patients with HAV infection. It consists of severe acute liver injury with encephalopathy and impaired synthetic function and occurs most commonly in individuals &gt;50 years of age and individuals with other liver diseases such as hepatitis B or C. Patients with fulminant hepatic failure should be transferred to a center capable of performing liver transplantation. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3574.html" rel="external">
          "Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory abnormalities
         </strong>
         − Laboratory abnormalities include elevations of serum aminotransferases (often &gt;1000 international units/dL), followed by elevations of serum bilirubin (up to 10 mg/dL). Serum aminotransferases peak approximately one month after exposure to the virus and then decline by approximately 75 percent per week. The serum bilirubin concentration usually declines within two weeks of peak levels. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         − The diagnosis of acute HAV infection should be suspected in patients with abrupt onset of gastrointestinal signs and symptoms and jaundice or elevated serum aminotransferase levels, particularly in the setting of known risk factors for hepatitis A transmission  (
         <a class="graphic graphic_table graphicRef80824" href="/z/d/graphic/80824.html" rel="external">
          table 1
         </a>
         ). The diagnosis is established by detection of serum immunoglobulin (Ig)M anti-HAV antibodies. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H176781247">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Catherine P Cheney, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           MacCallum FO. Homologous serum jaundice. Lancet 1947; 2:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 1973; 182:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Damme P, Pintó RM, Feng Z, et al. Hepatitis A virus infection. Nat Rev Dis Primers 2023; 9:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegl G, Weitz M, Kronauer G. Stability of hepatitis A virus. Intervirology 1984; 22:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid TM, Robinson HG. Frozen raspberries and hepatitis A. Epidemiol Infect 1987; 98:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattar SA, Jason T, Bidawid S, Farber J. Foodborne spread of hepatitis A: Recent studies on virus survival, transfer and inactivation. Can J Infect Dis 2000; 11:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCaustland KA, Bond WW, Bradley DW, et al. Survival of hepatitis A virus in feces after drying and storage for 1 month. J Clin Microbiol 1982; 16:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brundage SC, Fitzpatrick AN. Hepatitis A. Am Fam Physician 2006; 73:2162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniels D, Grytdal S, Wasley A, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009; 58:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klevens RM, Miller JT, Iqbal K, et al. The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005-2007. Arch Intern Med 2010; 170:1811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohm SR, Berger KW, Hackert PB, et al. Hepatitis A outbreak among adults with developmental disabilities in group homes--Michigan, 2013. MMWR Morb Mortal Wkly Rep 2015; 64:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latash J, Dorsinville M, Del Rosso P, et al. Notes from the Field: Increase in Reported Hepatitis A Infections Among Men Who Have Sex with Men - New York City, January-August 2017. MMWR Morb Mortal Wkly Rep 2017; 66:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett CE, Pape BJ, Benedict KM, et al. Impact of Public Health Interventions on Drinking Water-Associated Outbreaks of Hepatitis A - United States, 1971-2017. MMWR Morb Mortal Wkly Rep 2019; 68:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemmer NM, Miskovsky EP. Hepatitis A. Infect Dis Clin North Am 2000; 14:605.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Viral Hepatitis Surveillance: United States, 2013. US Department of Health and Human Services, Atlanta, GA 2016. https://www.cdc.gov/hepatitis/statistics/2014surveillance/pdfs/2014HepSurveillanceRpt_Rev2016-09-26.pdf (Accessed on September 11, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor RM, Davern T, Munoz S, et al. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology 2006; 44:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Global Alert and Response (GAR): Hepatitis A. http://www.who.int/csr/disease/hepatitis/whocdscsredc2007/en/index4.html#estimated (Accessed on July 13, 2016).
         </li>
         <li class="breakAll">
          World Health Organization. WHO position paper on hepatitis A vaccines – October 2022. Weekly Epidemiological Record 2022; 40:493. https://www.who.int/publications/i/item/who-wer9740-493-512 (Accessed on January 29, 2024).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev 2001; 14:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helmick MJ, Morrow CB, White JH, Bordwine P. Widespread Community Transmission of Hepatitis A Virus Following an Outbreak at a Local Restaurant - Virginia, September 2021-September 2022. MMWR Morb Mortal Wkly Rep 2023; 72:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wensley A, Smout E, Ngui SL, et al. An outbreak of hepatitis A virus infection in a secondary school in England with no undetected asymptomatic transmission among students. Epidemiol Infect 2022; 151:e6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Neill C, Franklin N, Edwards A, et al. Hepatitis A outbreak in Australia linked to imported Medjool dates, June-September 2021. Commun Dis Intell (2018) 2022; 46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McClure M, Nsubuga J, Montgomery MP, et al. A 2019 Outbreak Investigation of Hepatitis A Virus Infections in the United States Linked to Imported Fresh Blackberries. Food Environ Virol 2022; 14:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Son H, Lee M, Eun Y, et al. An outbreak of hepatitis A associated with salted clams in Busan, Korea. Epidemiol Health 2022; 44:e2022003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia Vilaplana T, Leeman D, Balogun K, et al. Hepatitis A outbreak associated with consumption of dates, England and Wales, January 2021 to April 2021. Euro Surveill 2021; 26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruscher C, Faber M, Werber D, et al. Resurgence of an international hepatitis A outbreak linked to imported frozen strawberries, Germany, 2018 to 2020. Euro Surveill 2020; 25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chodick G, Ashkenazi S, Lerman Y. The risk of hepatitis A infection among healthcare workers: a review of reported outbreaks and sero-epidemiologic studies. J Hosp Infect 2006; 62:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiseman R, Weil LM, Lozano C, et al. Notes from the Field: Health Care-Associated Hepatitis A Outbreak - Texas, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kushel M. Hepatitis A Outbreak in California - Addressing the Root Cause. N Engl J Med 2018; 378:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster M, Ramachandran S, Myatt K, et al. Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness - California, Kentucky, Michigan, and Utah, 2017. MMWR Morb Mortal Wkly Rep 2018; 67:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster MA, Hofmeister MG, Kupronis BA, et al. Increase in Hepatitis A Virus Infections - United States, 2013-2018. MMWR Morb Mortal Wkly Rep 2019; 68:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster MA, Hofmeister MG, Albertson JP, et al. Hepatitis A Virus Infections Among Men Who Have Sex with Men - Eight U.S. States, 2017-2018. MMWR Morb Mortal Wkly Rep 2021; 70:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28:6653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutin YJ, Pool V, Cramer EH, et al. A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team. N Engl J Med 1999; 340:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005; 294:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mutsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988-2004. Clin Infect Dis 2006; 42:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ly KN, Klevens RM. Trends in disease and complications of hepatitis A virus infection in the United States, 1999-2011: a new concern for adults. J Infect Dis 2015; 212:176.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Hepatitis A Questions and Answers for Health Professionals. http://www.cdc.gov/hepatitis/hav/havfaq.htm#general (Accessed on July 13, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy TV, Denniston MM, Hill HA, et al. Progress Toward Eliminating Hepatitis A Disease in the United States. MMWR Suppl 2016; 65:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Z, Chen Y, Xie S, Lv H. Changing Epidemiological Characteristics of Hepatitis A in Zhejiang Province, China: Increased Susceptibility in Adults. PLoS One 2016; 11:e0153804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallbracht A, Fleischer B, Busch FW. Hepatitis A: hepatotropism and influence on myelopoiesis. Intervirology 1993; 35:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleischer B, Fleischer S, Maier K, et al. Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology 1990; 69:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baba M, Hasegawa H, Nakayabu M, et al. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. J Clin Lab Immunol 1993; 40:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rezende G, Roque-Afonso AM, Samuel D, et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 2003; 38:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med 1985; 313:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985; 122:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 1995; 171 Suppl 1:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elinav E, Ben-Dov IZ, Shapira Y, et al. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology 2006; 130:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992; 10 Suppl 1:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson M, Elliman D, Maguire H, et al. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J 2001; 20:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inman RD, Hodge M, Johnston ME, et al. Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection. Ann Intern Med 1986; 105:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dan M, Yaniv R. Cholestatic hepatitis, cutaneous vasculitis, and vascular deposits of immunoglobulin M and complement associated with hepatitis A virus infection. Am J Med 1990; 89:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 1992; 10 Suppl 1:S18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ilan Y, Hillman M, Oren R, et al. Vasculitis and cryoglobulinemia associated with persisting cholestatic hepatitis A virus infection. Am J Gastroenterol 1990; 85:586.
          </a>
         </li>
         <li class="breakAll">
          Lavine J, Bull F, Millward-Sadler G. Acute viral hepatitis. In: Wright's Liver and Biliary Disease, Millard-Sadler G, Wright R, Arthur M (Eds), WB Saunders, London 1992. p.681.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shenoy R, Nair S, Kamath N. Thrombocytopenia in hepatitis A--an atypical presentation. J Trop Pediatr 2004; 50:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon SC, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984; 101:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung YM, Park SJ, Kim JS, et al. Atypical manifestations of hepatitis A infection: a prospective, multicenter study in Korea. J Med Virol 2010; 82:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiraldi O, Modugno A, Miglietta A, Fera G. Prolonged viral hepatitis type A with cholestasis: case report. Ital J Gastroenterol 1991; 23:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glikson M, Galun E, Oren R, et al. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore) 1992; 71:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassas AL, Telegdy L, Méhesfalvi E, et al. Polyphasic and protracted patterns of hepatitis A infection: a retrospective study. Acta Med Hung 1994; 50:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bornstein JD, Byrd DE, Trotter JF. Relapsing hepatitis A: a case report and review of the literature. J Clin Gastroenterol 1999; 28:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grünhage F, Spengler U, Fischer HP, Sauerbruch T. Autoimmune hepatitis--sequel of a relapsing hepatitis A in a 75-year-old woman. Digestion 2004; 70:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sjogren MH, Tanno H, Fay O, et al. Hepatitis A virus in stool during clinical relapse. Ann Intern Med 1987; 106:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rachima CM, Cohen E, Garty M. Acute hepatitis A: combination of the relapsing and the cholestatic forms, two rare variants. Am J Med Sci 2000; 319:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991; 337:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skoog SM, Rivard RE, Batts KP, Smith CI. Autoimmune hepatitis preceded by acute hepatitis A infection. Am J Gastroenterol 2002; 97:1568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis--United States, 2002-2004. MMWR Morb Mortal Wkly Rep 2005; 54:453.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2692 Version 49.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Homologous serum jaundice
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4356028" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37770459" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hepatitis A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6096294" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Stability of hepatitis A virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3030789" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Frozen raspberries and hepatitis A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18159284" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Foodborne spread of hepatitis A: Recent studies on virus survival, transfer and inactivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6296198" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Survival of hepatitis A virus in feces after drying and storage for 1 month.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16848078" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hepatitis A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19478727" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Surveillance for acute viral hepatitis - United States, 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21059974" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25695320" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hepatitis A outbreak among adults with developmental disabilities in group homes--Michigan, 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28934181" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Notes from the Field: Increase in Reported Hepatitis A Infections Among Men Who Have Sex with Men - New York City, January-August 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31487277" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Impact of Public Health Interventions on Drinking Water-Associated Outbreaks of Hepatitis A - United States, 1971-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10987112" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hepatitis A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10987112" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hepatitis A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17133489" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9445408" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9445408" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9445408" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11148002" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hepatitis A: old and new.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37022982" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Widespread Community Transmission of Hepatitis A Virus Following an Outbreak at a Local Restaurant - Virginia, September 2021-September 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36502811" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : An outbreak of hepatitis A virus infection in a secondary school in England with no undetected asymptomatic transmission among students.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36303398" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hepatitis A outbreak in Australia linked to imported Medjool dates, June-September 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35871245" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A 2019 Outbreak Investigation of Hepatitis A Virus Infections in the United States Linked to Imported Fresh Blackberries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34990534" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : An outbreak of hepatitis A associated with salted clams in Busan, Korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34018484" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hepatitis A outbreak associated with consumption of dates, England and Wales, January 2021 to April 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32945256" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Resurgence of an international hepatitis A outbreak linked to imported frozen strawberries, Germany, 2018 to 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16488511" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The risk of hepatitis A infection among healthcare workers: a review of reported outbreaks and sero-epidemiologic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27123787" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Notes from the Field: Health Care-Associated Hepatitis A Outbreak - Texas, 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29211622" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hepatitis A Outbreak in California - Addressing the Root Cause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30383739" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness - California, Kentucky, Michigan, and Utah, 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31071072" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Increase in Hepatitis A Virus Infections - United States, 2013-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34138829" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hepatitis A Virus Infections Among Men Who Have Sex with Men - Eight U.S. States, 2017-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32614811" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20723630" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Hepatitis A virus seroprevalence by age and world region, 1990 and 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10029643" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16014593" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Incidence of hepatitis A in the United States in the era of vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16708058" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16421793" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hepatitis A virus infections in travelers, 1988-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25637352" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Trends in disease and complications of hepatitis A virus infection in the United States, 1999-2011: a new concern for adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25637352" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Trends in disease and complications of hepatitis A virus infection in the United States, 1999-2011: a new concern for adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26916458" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Progress Toward Eliminating Hepatitis A Disease in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27093614" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Changing Epidemiological Characteristics of Hepatitis A in Zhejiang Province, China: Increased Susceptibility in Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8407240" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Hepatitis A: hepatotropism and influence on myelopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2312151" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7932628" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12939587" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Viral and clinical factors associated with the fulminant course of hepatitis A infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2413356" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Type A viral hepatitis. New developments in an old disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3860002" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Frequency of illness associated with epidemic hepatitis A virus infections in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7876641" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clinical manifestations of hepatitis A: recent experience in a community teaching hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16618407" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1335649" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical manifestations and diagnosis of hepatitis A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11332662" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3021038" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2368780" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Cholestatic hepatitis, cutaneous vasculitis, and vascular deposits of immunoglobulin M and complement associated with hepatitis A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1475999" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Atypical clinical manifestations of hepatitis A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2337062" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Vasculitis and cryoglobulinemia associated with persisting cholestatic hepatitis A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2337062" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Vasculitis and cryoglobulinemia associated with persisting cholestatic hepatitis A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15357567" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Thrombocytopenia in hepatitis A--an atypical presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6486595" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prolonged intrahepatic cholestasis secondary to acute hepatitis A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20572083" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Atypical manifestations of hepatitis A infection: a prospective, multicenter study in Korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1742530" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Prolonged viral hepatitis type A with cholestasis: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1312659" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Relapsing hepatitis A. Review of 14 cases and literature survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7638046" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Polyphasic and protracted patterns of hepatitis A infection: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10372936" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Relapsing hepatitis A: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15557764" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Autoimmune hepatitis--sequel of a relapsing hepatitis A in a 75-year-old woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3026213" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Hepatitis A virus in stool during clinical relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10875301" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Acute hepatitis A: combination of the relapsing and the cholestatic forms, two rare variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1673738" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12094893" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Autoimmune hepatitis preceded by acute hepatitis A infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15889006" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis--United States, 2002-2004.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
